1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hypopharyngeal Cancer Global Clinical Trials Review, H1, 2014

Hypopharyngeal Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Hypopharyngeal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hypopharyngeal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hypopharyngeal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hypopharyngeal Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Hypopharyngeal Cancer Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Hypopharyngeal Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Hypopharyngeal Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Hypopharyngeal Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Hypopharyngeal Cancer 24
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Hypopharyngeal Cancer Therapeutics Clinical Trials 30
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
C. H. Boehringer Sohn AG and Co. KG 32
Clinical Trial Overview of C. H. Boehringer Sohn AG and Co. KG 32
Pharmacyclics, Inc. 33
Clinical Trial Overview of Pharmacyclics, Inc. 33
CellAct Pharma GmbH 34
Clinical Trial Overview of CellAct Pharma GmbH 34
Boehringer Ingelheim GmbH 35
Clinical Trial Overview of Boehringer Ingelheim GmbH 35
Clinical Trial Overview of Top Institutes / Government 36
National Cancer Institute 36
Clinical Trial Overview of National Cancer Institute 36
European Organization for Research and Treatment of Cancer 38
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 38
The University of Texas M. D. Anderson Cancer Center 39
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 39
University of Washington 40
Clinical Trial Overview of University of Washington 40
National Taiwan University Hospital 41
Clinical Trial Overview of National Taiwan University Hospital 41
Ohio State University Comprehensive Cancer Center 42
Clinical Trial Overview of Ohio State University Comprehensive Cancer Center 42
Groupe Oncologie Radiotherapie Tete et Cou 43
Clinical Trial Overview of Groupe Oncologie Radiotherapie Tete et Cou 43
University of Alabama at Birmingham 44
Clinical Trial Overview of University of Alabama at Birmingham 44
Fox Chase Cancer Center 45
Clinical Trial Overview of Fox Chase Cancer Center 45
Radboud University 46
Clinical Trial Overview of Radboud University 46
Five Key Clinical Profiles 47
Appendix 112
Abbreviations 112
Definitions 112
Research Methodology 113
Secondary Research 113
About GlobalData 114
Contact Us 114
Disclaimer 114
Source 115

List of Tables
Hypopharyngeal Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Hypopharyngeal Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Hypopharyngeal Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Hypopharyngeal Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Hypopharyngeal Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Hypopharyngeal Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Hypopharyngeal Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Hypopharyngeal Cancer Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Hypopharyngeal Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Hypopharyngeal Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Hypopharyngeal Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Hypopharyngeal Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Hypopharyngeal Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Hypopharyngeal Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Hypopharyngeal Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Hypopharyngeal Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Hypopharyngeal Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Hypopharyngeal Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 24
Hypopharyngeal Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 24
Hypopharyngeal Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Hypopharyngeal Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Hypopharyngeal Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Hypopharyngeal Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Hypopharyngeal Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Hypopharyngeal Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG and Co. KG, 2014* 32
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014* 33
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by CellAct Pharma GmbH, 2014* 34
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Boehringer Ingelheim GmbH, 2014* 35
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 36
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 38
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 39
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 40
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 41
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Ohio State University Comprehensive Cancer Center, 2014* 42
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Groupe Oncologie Radiotherapie Tete et Cou, 2014* 43
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Alabama at Birmingham, 2014* 44
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Fox Chase Cancer Center, 2014* 45
Hypopharyngeal Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Radboud University, 2014* 46

List of Figures
Hypopharyngeal Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Hypopharyngeal Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Hypopharyngeal Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Hypopharyngeal Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Hypopharyngeal Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Hypopharyngeal Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Hypopharyngeal Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Hypopharyngeal Cancer Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Hypopharyngeal Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Hypopharyngeal Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Hypopharyngeal Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Hypopharyngeal Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Hypopharyngeal Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Hypopharyngeal Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Hypopharyngeal Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Hypopharyngeal Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Hypopharyngeal Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Hypopharyngeal Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Hypopharyngeal Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Hypopharyngeal Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Hypopharyngeal Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 113

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.